Background: The effects of physiological changes in patients with obesity on pharmacokinetic parameters and the time course of drug response, especially in the field of haematology/oncology, are poorly understood. For some antimicrobial drugs, dosing considerations exist, while for cytostatic drugs, dose modifications for obese patients are not consistently recommended. Glomerular filtration rate and renal perfusion appear to be similar in obese and normal weight individuals, thus elimination of hydrophilic and extensively renally cleared drugs mainly depends upon creatinine clearance.
Aim Of The Review: To provide information about drug dosing in morbidly obese patients undergoing allogenic haematopoietic stem cell transplantation and to develop dosing recommendations for those patients, based on literature data, pharmacokinetic properties and own experiences.
Method: A review on the literature on drug dosing in obese patients as well as on the pharmacokinetic properties of drugs which are supposed to be used in the field of stem cell transplantation was combined with own data on drug dosing and pharmacokinetic drug monitoring in a morbidly obese patient undergoing matched-unrelated allogenic peripheral blood stem cell transplantation.
Results: For hydrophilic and extensively renally cleared drugs (e.g. piperacillin/sulbactam, cotrimoxazole, fludarabine) standard dosages for adult patients or dosing based on ideal body weight (IBW) (e.g. aciclovir, methotrexate) can be used. For ciclosporin and digitoxin we could show that high initial doses are needed to achieve sufficient plasma concentrations. After steady state distribution was completed, maintenance doses comparable to normal weight patients are sufficient. Likewise, distribution of enoxaparin and phenytoin seems to take longer in obese patients. Dosing recommendations of 25 drugs that can be used in morbidly obese patients undergoing allogenic stem cell transplantation are given.
Conclusions: Pharmacotherapy in morbidly obese patients undergoing allogenic stem cell transplantation is possible, if pharmacokinetic properties of the drugs are considered and close monitoring of plasma concentrations is performed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11096-011-9568-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and histopathological evaluation of patients with endometrial cancer in a University Hospital: Seven-year experience.
Malays J Pathol
December 2024
Universiti Sains Malaysia, School of Medical Sciences, Department of Obstetrics & Gynaecology, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.
Introduction: Endometrial cancer is one of the leading gynaecological malignancies in developed countries and becoming more prevalent in Malaysia. These have significant impact in women and management of this disease. If it occurs on young women, and as a whole becomes a burden on the national economy and world.
View Article and Find Full Text PDF[A portrait of a doctor with Parkinson's disease].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Siberian State Medical University, Tomsk, Russia.
In a number of causes of Parkinson's disease (PD), occupation is periodically mentioned as a possible risk factor. However, a look at the complex impact of external factors on people of certain professions and the expansion of the area of risk factors in a rapidly changing world leads to the emergence of new studies. There is an assumption that the risk of developing PD is increased in doctors due to long-term exposure to stress.
View Article and Find Full Text PDFDeveloping a Charlson Comorbidity Index for the American Indian Population Using the Epidemiologic Data from the Strong Heart Study.
J Racial Ethn Health Disparities
December 2024
Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Background: The Charlson Comorbidity Index (CCI) is a frequently used mortality predictor based on a scoring system for the number and type of patient comorbidities health researchers have used since the late 1980s. The initial purpose of the CCI was to classify comorbid conditions, which could alter the risk of patient mortality within a 1-year time frame. However, the CCI may not accurately reflect risk among American Indians because they are a small proportion of the US population and possibly lack representation in the original patient cohort.
View Article and Find Full Text PDFBackground: This study aimed to compare outcomes following antral preserving (AP) and antral resecting (AR) laparoscopic sleeve gastrectomy (LSG) in terms of weight loss, gastric emptying time, gastroesophageal reflux disease (GERD), resolution of associated medical problems, and complications.
Methods: Patients were prospectively randomized into two groups: the AR group (resection starting 2 cm from the pylorus) and the AP group (resection at 5 cm from the pylorus). Follow-up evaluations included assessments of weight loss using percentage of excess weight loss (%EWL) and percentage of total weight loss (%TWL), gastric emptying, GERD symptoms, associated medical problem resolution, residual gastric volume, and complications.
Outcomes and complications after long versus short gastric pouch Roux-en-Y gastric bypass in patients with severe obesity.
Sci Rep
December 2024
Department of Surgery, Minimally Invasive Surgery Research Center, Division of Minimally Invasive and Bariatric Surgery, Hazrat-E Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Roux-en-Y gastric bypass (RYGB) is the second most common metabolic and bariatric surgery (MBS) globally. The impact of pouch size on weight loss outcomes and complications remains unclear. This study aims to compare the weight loss outcomes and complications in long pouch versus short pouch RYGB in patients with severe obesity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!